Abstract: This invention is related to new nitrogenated trans-stilbene compounds, more specifically, imine, pyrrole and indole derivatives, with procedures for the preparation and use thereof as pharmaceutical compositions for the treatment and/or chemoprevention of those mammalian diseases such as cancer, fibrosclerosis and acute/chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury in stroke and heart attack, neurodegeneration, and during organ transplantation, whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable oxidative stress, angiogenic and proliferative responses.

Abstract: The invention relates to a process for obtaining hydrogen from natural gas which comprises (a) reacting the natural gas with a mixture of air and steam in a single reactor to obtain a gas comprising H2 and CO, (b) reacting the CO produced at a high temperature with steam to obtain a gas comprising H2 and CO2, and (c) reacting the CO which has not reacted in step (b) at a low temperature with steam to obtain a gas comprising H2 and CO2, characterized in that in step (a) the natural gas, the air and the steam are fed simultaneously and react on the same catalyst and in that the pressure used in steps (a) to (c) varies between 1 and 8 atm, as well as to a H2 production plant for carrying out the mentioned process.

Abstract: The invention relates to a method for quantifying G protein-coupled receptor (GPCR)-G protein binding by means of using a cell membrane array, which comprises (i) putting an unlabeled candidate compound in contact with a cell membrane array in the presence of labeled GTP or of a labeled, non-hydrolyzable analog thereof, in conditions allowing the interaction between said compound and said GPCR present in said cell membranes, and between said labeled GTP or analog thereof and said G protein present in said membranes; (ii) washing; and (iii) quantifying the signal obtained due to the binding of the labeled GTP (or analog) to said G protein. It is applicable in the analysis of the interaction between compounds and cell membrane receptor proteins and of the intracellular signaling mechanisms triggering this interaction mechanism mediated by said compounds.

Abstract: The present invention relates to methods for the treatment of neurodegenerative diseases by means of the use of microparticles comprising genetically modified cells expressing neurotrophic and/or angiogenic factors and wherein said microparticles are administered by means of implantation at the cerebral cortex level.

Abstract: The invention relates to an in vitro method for the detection of bacteria of the Salmonella spp. genus by means of a quantitative polymerase chain reaction using specific primers for said pathogen from DNA and RNA samples from said microorganism. Said method is useful in the detection of viable and non-viable microorganisms of Salmonella spp. in environmental, clinical and food samples. Likewise, the invention also relates to a kit used for putting said method into practice.

Abstract: The invention relates to an integral magnetic compass for obtaining deviations in real time, formed by a transparent sphere or cylinder (2), incorporating therein, in a hydrocarbon liquid (3), a polyester or silicon disk (4) to which the rose (5) and the magnet (6) are fitted, being associated with a commutation system formed by integrated software in a device or chip (7), the circuit of which has two inputs: an input (8) to the signal obtained from the magnetic compass (1) itself, obtained by means of a magnetometer (9) or optical reader (10) in association therewith, and another input (11) to the signal from the satellite compass (12) or from the gyroscopic compass (13), and said circuit having an output (14) to a display (15) for viewing and storage of the data for the corresponding deviations, thus obtaining the deviation chart for the magnetic needle in real time, said output being also applicable to the automatic pilot (16).

Abstract: This invention is related to new nitrogenated trans-stilbene compounds, more specifically, imine, pyrrole and indole derivatives, with procedures for the preparation and use thereof as pharmaceutical compositions for the treatment and/or chemoprevention of those mammalian diseases such as cancer, fibrosclerosis and acute/chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury in stroke and heart attack, neurodegeneration, and during organ transplantation, whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable oxidative stress, angiogenic and proliferative responses.

Abstract: The present invention refers to the use of glutamate transporters, glutamate and EGF to detect the presence of demyelinating diseases in a subject, to determine the status or severity of the same or to monitor the effects of a therapy administered to a subject who suffers from such diseases; to the use of the said markers for the searching, identification, development and evaluation of the efficacy of compounds for the treatment of such diseases, with a view to developing new drugs; to the use of compounds which promote the expression of the EAAT1 and EAAT2 transporters, as well as EGF for the treatment of demyelinating diseases. In a preferred embodiment, the methods and compounds of the invention are applicable to MS.

Abstract: The adrenergic receptors or adrenoceptors are a family of G-protein coupled receptors split into ? and ? subclasses. The adrenoceptors have important roles in regulating a myriad of physiological conditions and their malfunction has been implicated in the pathophysiology of a number of diseases. Disclosed herein are a series of novel guanidine and 2-aminoimidazoline compounds which are ligands of the alpha2-adrenoceptor (?2-ARs) subclass of adrenergic receptors. The invention also provides for pharmaceutical compositions comprising the novel compounds. The compounds are suitable for use in the manufacture of medicaments for the treatment of ?2-ARs associated disorders, such as depression, schizophrenia, glaucoma and analgesia.

Abstract: The invention relates to microparticles based on a PLGA biodegradable polymer and an alginate polymer which encapsulate immunologically active peptides or proteins. Said microparticles, and the pharmaceutical compositions developed from them and the uses thereof, are applicable to the field of human and animal health as a vaccine and system for releasing biologically active molecules.

Abstract: The present invention relates to the use of adenylate cyclase toxin (ACT), or a functionally equivalent variant thereof, as an inducing agent for the internalization of non-invasive bacteria in eukaryotic cells. Due to ACT, said non-invasive bacterium can move through the plasma membrane of a eukaryotic cell and transfer plasmid DNA to said cell, which is useful for releasing or introducing molecules of therapeutic interest, for example, antigens, in the interior of the eukaryotic cell, thereby triggering the immune response.

Abstract: The object of the present invention is to provide particles of a polymeric material containing cells therein, wherein said particles have a strength that is substantially greater than the microcapsules known in the state of the art.

Abstract: The biocompatible microgels comprises a polymeric network, said polymeric network comprising monomeric units interconnected with one another through a crosslinking agent, wherein said polymeric network can be obtained by polymerization in a dispersed medium of a biocompatible vinyl monomer and a crosslinking agent. The microgel may further comprise a biologically active agent. Said biocompatible microgels can be used, among other applications, to transport and dose biologically active agents.

Abstract: The invention describes an in vitro method for detecting a psychiatric disorder occurring with psychosis selected from schizophrenia and bipolar disorder in an individual who has suffered a first psychotic episode, or for determining the state or severity of said disorder, or for monitoring the effect of a therapy administered to an individual who suffers said disorder, or for evaluating the predisposition of an individual presenting a prodromal symptom to develop said disorder, based on the use of the brain-derived neutrophic factor (BDNF) as a marker.

Abstract: The invention describes new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases.

Abstract: The invention relates to the use of morin and mangiferin, the pharmaceutically acceptable salts, prodrugs and/or solvates thereof in the production of a pharmaceutical composition for the prevention and/or treatment of a neurodegenerative disease and symptoms associated with ageing, as well as to food compositions comprising said compounds.

Abstract: The invention relates to a metal matrix material based on shape-memory alloy powders, to the production method thereof and to the use of same. More specifically, the invention relates to a metal matrix material which is characterised in that it is based on particles of shape-memory alloy powder, having a base of copper at a concentration of between 45 vol.-% and 70 vol.-% in relation to the total volume of the material, said powder particles being supported by a metal matrix. The invention also relates to a method of producing the aforementioned material and to the use of same for absorbing vibrations, particularly acoustic and mechanical vibrations.

Abstract: The invention relates to a process for obtaining hydrogen from natural gas which comprises (a) reacting the natural gas with a mixture of air and steam in a single reactor to obtain a gas comprising H2 and CO, (b) reacting the CO produced at a high temperature with steam to obtain a gas comprising H2 and CO2, and (c) reacting the CO which has not reacted in step (b) at a low temperature with steam to obtain a gas comprising H2 and CO2, characterized in that in step (a) the natural gas, the air and the steam are fed simultaneously and react on the same catalyst and in that the pressure used in steps (a) to (c) varies between 1 and 8 atm, as well as to a H2 production plant for carrying out the mentioned process.

Abstract: The invention relates to a method for quantifying G protein-coupled receptor (GPCR)-G protein binding by means of using a cell membrane array, which comprises (i) putting an unlabeled candidate compound in contact with a cell membrane array in the presence of labeled GTP or of a labeled, non-hydrolyzable analog thereof, in conditions allowing the interaction between said compound and said GPCR present in said cell membranes, and between said labeled GTP or analog thereof and said G protein present in said membranes; (ii) washing; and (iii) quantifying the signal obtained due to the binding of the labeled GTP (or analog) to said G protein. It is applicable in the analysis of the interaction between compounds and cell membrane receptor proteins and of the intracellular signaling mechanisms triggering this interaction mechanism mediated by said compounds.

Abstract: This invention relates to nitroproline derivative compounds and procedures for their preparation and the preparation of pharmaceutical compositions containing the compounds. The invention also relates to the administration of compounds of the invention as agents for the treatment of mammalian diseases whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable cellular and molecular activities or responses induced by integrin-dependent molecular interactions.